Gland Pharma Limited receives EIR from USFDA for Dundigal Facility

Following the 'Good Manufacturing Practice (GMP) Inspection' by US FDA at Gland Pharma Limited's Dundigal Facility at Hyderabad between 03rd July, 2023 and 14th July, 2023; the Company has received Establishment Inspection Report (EIR) from the US FDA indicating closure of the inspection.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1581.35 as compared to the previous close of Rs. 1606.10. The total number of shares traded during the day was 14651 in over 1921 trades.

The stock hit an intraday high of Rs. 1612.00 and intraday low of 1571.55. The net turnover during the day was Rs. 23300106.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 EIR USFDA DundigalFacility